30
NOV

2009 Minerva grants Clarient exclusive commercialization rights to its MUC1 diagnostic test.

11
may

2009.Herceptin paper. The Journal of Breast Cancer Research and Treatment, “MUC1* is a Determinant of Trastuzumab (Herceptin) Resistance in Breast Cancer Cells”

25
jul

2008. Stem Cell paper. PLoSone Publishes Minerva stem cell research article.

29
apr

2008..Cancer paper. PLoSone Publishes Minerva cancer research article.

18
jun

2007..Osmetech grants research license. Osmetech PLC said it has granted...